Literature DB >> 26179086

Mineral Levels in Thalassaemia Major Patients Using Different Iron Chelators.

Gizem Esra Genc1, Zeynep Ozturk1, Saadet Gumuslu2, Alphan Kupesiz1.   

Abstract

The goal of the present study was to determine the levels of minerals in chronically transfused thalassaemic patients living in Antalya, Turkey and to determine mineral levels in groups using different iron chelators. Three iron chelators deferoxamine, deferiprone and deferasirox have been used to remove iron from patients' tissues. There were contradictory results in the literature about minerals including selenium, zinc, copper, and magnesium in thalassaemia major patients. Blood samples from the 60 thalassaemia major patients (the deferoxamine group, n = 19; the deferiprone group, n = 20 and the deferasirox group, n = 21) and the controls (n = 20) were collected. Levels of selenium, zinc, copper, magnesium, and iron were measured, and all of them except iron showed no significant difference between the controls and the patients regardless of chelator type. Serum copper levels in the deferasirox group were lower than those in the control and deferoxamine groups, and serum magnesium levels in the deferasirox group were higher than those in the control, deferoxamine and deferiprone groups. Iron levels in the patient groups were higher than those in the control group, and iron levels showed a significant correlation with selenium and magnesium levels. Different values of minerals in thalassaemia major patients may be the result of different dietary intake, chelator type, or regional differences in where patients live. That is why minerals may be measured in thalassaemia major patients at intervals, and deficient minerals should be replaced. Being careful about levels of copper and magnesium in thalassaemia major patients using deferasirox seems to be beneficial.

Entities:  

Keywords:  Copper; Iron; Iron chelator; Magnesium; Selenium; Thalassaemia; Zinc

Mesh:

Substances:

Year:  2015        PMID: 26179086     DOI: 10.1007/s12011-015-0441-1

Source DB:  PubMed          Journal:  Biol Trace Elem Res        ISSN: 0163-4984            Impact factor:   3.738


  4 in total

Review 1.  Deferasirox for managing iron overload in people with thalassaemia.

Authors:  Claudia Bollig; Lisa K Schell; Gerta Rücker; Roman Allert; Edith Motschall; Charlotte M Niemeyer; Dirk Bassler; Joerg J Meerpohl
Journal:  Cochrane Database Syst Rev       Date:  2017-08-15

2.  Nutrition in Thalassemia: A Systematic Review of Deficiency, Relations to Morbidity, and Supplementation Recommendations.

Authors:  Elijah K Goldberg; Ashutosh Lal; Ellen B Fung
Journal:  J Pediatr Hematol Oncol       Date:  2022-01-01       Impact factor: 1.289

3.  Ocular manifestations in patients with transfusion-dependent β-thalassemia.

Authors:  F Akritidou; A Praidou; T Papamitsou; V Kozobolis; G Labiris
Journal:  Hippokratia       Date:  2021 Apr-Jun       Impact factor: 0.522

Review 4.  Vitamin and mineral supplementation for β-thalassemia during COVID-19 pandemic.

Authors:  Annette d'Arqom; Melvanda G Putri; Yovani Savitri; Andi Muh Rahul Alfaidin
Journal:  Future Sci OA       Date:  2020-08-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.